Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
ID: 357190Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357190

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-25-173.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE), aimed at supporting innovative preclinical research projects that investigate the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and the tumor microenvironment. This initiative encourages proposals that explore new targets for radiopharmaceuticals, develop drug combination strategies, and enhance theranostic capabilities, with a budget cap of $275,000 over a two-year period. The STRIPE program is critical for advancing cancer treatment methodologies by facilitating the transition of promising preclinical findings into clinical applications. Interested applicants can submit proposals starting January 16, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-25-173-Full-Announcement.html
    PA-25-173.html
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE), managed by the National Cancer Institute (NCI). This initiative aims to support R21 research projects that investigate the effects of various types of radiation used in radionuclide-based therapeutics on normal tissues, tumor cells, and the tumor microenvironment. Applicants can submit proposals starting January 16, 2025, with a budget cap of $275,000 over two years, focusing on novel preclinical research rather than clinical trials. Key research priorities include exploring new targets for radiopharmaceuticals, developing drug combination strategies, and enhancing theranostic capabilities. Collaborative proposals are encouraged, particularly those involving multiple principal investigators with expertise in cancer biology and radiotherapy. Importantly, the STRIPE program seeks to advance preclinical studies, facilitating the transition of promising findings into clinical applications. The program emphasizes adherence to detailed application instructions and regulatory compliance to enhance research quality and effectiveness. This grant represents a significant opportunity for advancing cancer treatment methodologies through innovative research.
    Similar Opportunities
    Selective Precision Targeting (SPoT)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled Selective Precision Targeting (SPoT) aimed at advancing therapeutic drug delivery systems to specific hard-to-reach locations within the human body. This initiative seeks to optimize the targeting of nanoparticle therapeutics, assess biodistribution and off-target effects, provide evidence of functional cargo activity, and determine the optimal route of administration using microphysiological systems. With an estimated total program funding of $1.5 million and the expectation of awarding five grants, eligible small businesses are encouraged to apply. Interested applicants can reach out to Dr. Passley Hargrove-Grimes at passley.hargrove@nih.gov or by phone at 240-485-4149, with proposals due by February 17, 2026, and project start anticipated on January 18, 2027.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Centers (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a funding opportunity announcement for a cooperative agreement aimed at establishing a Network Radiotherapy and Imaging Core Services Center under the NCI National Clinical Trials Network (NCTN). This center will provide essential scientific and technical expertise for quality control, assurance, and image data management in NCTN trials that involve radiotherapy and imaging modalities, as well as support for other NCI-supported clinical trial programs. The funding opportunity is significant for enhancing cancer treatment research and is expected to have a total program funding of $8.8 million, with a ceiling of $8.14 million for the award. Interested private institutions of higher education should prepare their applications, as the anticipated application due date is in late February 2025, with an estimated award date set for March 1, 2026.
    Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity titled "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)," aimed at enhancing research experiences for resident clinicians in training. This initiative seeks to recruit, retain, and foster the independence of clinician-investigators by providing them with essential research opportunities early in their careers, thereby supporting basic, clinical, and translational research efforts. Although applications are not currently being solicited, potential applicants are encouraged to prepare meaningful collaborations and projects in anticipation of the forthcoming Notice of Funding Opportunity (NOFO). Interested parties can reach out to Dr. David Schopfer at david.schopfer@nih.gov or by phone at 301-402-3833 for further information, with the estimated synopsis posting date on July 11, 2025, and a projected award date of May 1, 2026.
    Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for R01 grant applications focused on the integration of imaging and fluid-based tumor monitoring in cancer therapy. The objective is to enhance research designs that utilize imaging and liquid biopsy assays to assess treatment responses and the emergence of resistance in cancer patients, thereby advancing precision medicine in cancer treatment. This initiative is critical for improving diagnostic techniques and patient monitoring strategies across various cancer types. Eligible applicants, including universities, for-profit organizations, and nonprofits, can apply for grants with a maximum budget of $500,000 per year for projects lasting up to five years. Applications will be accepted from January 5, 2025, until January 8, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at the development and application of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, specifically as biomarkers for drug discovery and studies related to central nervous system (CNS) disorders. This initiative invites applications focused on preclinical development, emphasizing the need for collaborative research between academia and industry to enhance understanding of brain disorders and support drug development processes. The funding opportunity is open to a diverse range of eligible institutions, including those serving underrepresented groups, with a submission deadline of May 7, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.